Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:43:17 22/05/2024 BST 5-day change 1st Jan Change
25.4 USD -1.21% Intraday chart for Intellia Therapeutics, Inc. -0.08% -15.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises MT
Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron DJ
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy CI
Transcript : Intellia Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM
North American Morning Briefing : Traders Await -2- DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating MT
Intellia Therapeutics Q4 Loss Widens MT
Transcript : Intellia Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating MT
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis CI
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study MT
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine CI
Transcript : Intellia Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM
Intellia Therapeutics Insider Sold Shares Worth $566,310, According to a Recent SEC Filing MT
Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees CI
Intellia Therapeutics Files Mixed Shelf MT
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy MT
Chart Intellia Therapeutics, Inc.
More charts
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
25.71 USD
Average target price
70.26 USD
Spread / Average Target
+173.28%
Consensus
  1. Stock Market
  2. Equities
  3. NTLA Stock
  4. News Intellia Therapeutics, Inc.
  5. Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals